Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00266760 · ClinicalTrials.gov registry record
Characteristics of Episodic Ataxia Syndrome
A clinical trial, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- 39
- Enrollment target
NCT00266760 is a clinical trial that has completed, run by University of California, Los Angeles. The registered enrollment target is 39 participants.
The verdict
NCT00266760 has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- 39 participants
- Enrollment target
Study Summary
Episodic ataxia (EA) is a rare genetic disease characterized by episodes of imbalance, incoordination, and slurring of speech. The underlying cause of EA is only partly understood, and currently there are no established treatments. There is also little information about the link between EA's clinical features and its genetic basis. The purpose of this study is to better characterize EA and disease progression. In turn, this may direct the development of future treatments.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2006-05 |
| Est. Completion | 2011-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00266760
The ClinicalTrials.gov registry entry for NCT00266760 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00266760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00266760 about?
NCT00266760 is a clinical study titled "Characteristics of Episodic Ataxia Syndrome". Episodic ataxia (EA) is a rare genetic disease characterized by episodes of imbalance, incoordination, and slurring of speech. The underlying cause of EA is only partly understood, and currently there are no established treatments. There is also little information about the link between EA's clinica...
What is the current status of trial NCT00266760?
This trial is currently completed. The enrollment target is 39 participants. The study started on 2006-05. Estimated completion is 2011-07.
Who is sponsoring clinical trial NCT00266760?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.